Filtered By:
Cancer: HER2
This page shows you your search results in order of relevance. This is page number 9.
Order by Relevance | Date
Total 260 results found since Jan 2013.
Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth
CONCLUSIONS: Our results indicate that EDI3 may be a potential novel therapeutic target in patients with HER2-targeted therapy-resistant ER-HER2 + breast cancer that should be further explored.PMID:36670508 | DOI:10.1186/s13046-022-02578-w
Source: Clinical Breast Cancer - January 20, 2023 Category: Cancer & Oncology Authors: Magdalena Keller Katharina Rohlf Annika Glotzbach Gregor Leonhardt Simon L üke Katharina Derksen Özlem Demirci Defne G öçener Mohammad AlWahsh J örg Lambert Cecilia Lindskog Marcus Schmidt Walburgis Brenner Matthias Baumann Eldar Zent Mia-Lisa Zischi Source Type: research
Budding uninhibited by benzimidazoles-1 (BUB1) regulates EGFR signaling by reducing EGFR internalization
Aging (Albany NY). 2023 Jul 3;15. doi: 10.18632/aging.204820. Online ahead of print.ABSTRACTEGFR signaling initiates upon ligand binding which leads to activation and internalization of the receptor-ligand complex. Here, we evaluated if BUB1 impacted EGFR signaling by regulating EGFR receptor internalization and activation. BUB1 was ablated genomically (siRNA) or biochemically (2OH-BNPP1) in cells. EGF ligand was used to initiate EGFR signaling while disuccinimidyl suberate (DSS) was used for cross linking cellular proteins. EGFR signaling was measured by western immunoblotting and receptor internalization was evaluated by...
Source: Aging - July 3, 2023 Category: Biomedical Science Authors: Shyam Nyati Grant Young Corey Speers Mukesh K Nyati Alnawaz Rehemtulla Source Type: research
Inhibiting HER3 Hyperphosphorylation in HER2 ‐Overexpressing Breast Cancer through Multimodal Therapy with Branched Gold Nanoshells
A multimodal theranostic nanoplatform to treat breast cancer overexpressing the human epidermal growth factor receptors 2 (HER2) and 3 (HER3) is developed, and consisting of doxorubicin-loaded branched gold nanoshells functionalized with a small interfering RNA against HER3 and the HER2-specific antibody Trastuzumab able to simultaneously combine chemo- and photothermal, RNA silencing and immuno-therapies overcoming chemoresistance and reducing tumor size in vivo. AbstractTreatment failure in breast cancers overexpressing human epidermal growth factor receptor 2 (HER2) is associated mainly to the upregulation of human epid...
Source: Small - August 26, 2023 Category: Nanotechnology Authors: Eva Villar ‐Alvarez,
Irene Golán‐Cancela,
Alberto Pardo,
Brenda Velasco,
Javier Fernández‐Vega,
Adriana Cambón,
Abeer Al‐Modlej,
Antonio Topete,
Silvia Barbosa,
José A. Costoya,
Pablo Taboada Tags: Research Article Source Type: research
WNT10B/β‐catenin signalling induces HMGA2 and proliferation in metastatic triple‐negative breast cancer
Abstract
Wnt/β‐catenin signalling has been suggested to be active in basal‐like breast cancer. However, in highly aggressive metastatic triple‐negative breast cancers (TNBC) the role of β‐catenin and the underlying mechanism(s) for the aggressiveness of TNBC remain unknown. We illustrate that WNT10B induces transcriptionally active β‐catenin in human TNBC and predicts survival‐outcome of patients with both TNBC and basal‐like tumours. We provide evidence that transgenic murine Wnt10b‐driven tumours are devoid of ERα, PR and HER2 expression and can model human TNBC. Importantly, HMGA2 is specifically exp...
Source: EMBO Molecular Medicine - January 11, 2013 Category: Molecular Biology Authors: Peter Wend, Stephanie Runke, Korinna Wend, Brenda Anchondo, Maria Yesayan, Meghan Jardon, Natalie Hardie, Christoph Loddenkemper, Ilya Ulasov, Maciej S. Lesniak, Rebecca Wolsky, Laurent A. Bentolila, Stephen G. Grant, David Elashoff, Stephan Lehr, Jean J. Tags: Research Article Source Type: research
Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies
Reis-Filho, C J Lord
& A Ashworth
Source: Oncogene - January 21, 2013 Category: Cancer & Oncology Authors: K-K ShiuD WetterskogA MackayR NatrajanM LambrosD SimsI BajramiR BroughJ FrankumR SharpeC MarchioH HorlingsF ReyalM van der VijverN TurnerJ S Reis-FilhoC J LordA Ashworth Tags: HER2-positive breast cancer microarrays gene expression comparative genomic hybridization siRNA screens TFAP2C Source Type: research
The RhoA pathway mediates MMP‐2 and MMP‐9‐independent invasive behavior in a triple‐negative breast cancer cell line
Abstract
Breast cancer is a heterogeneous disease that varies in its biology and response to therapy. A foremost threat to patients is tumor invasion and metastasis, with the greatest risk among patients diagnosed with triple‐negative and/or basal‐like breast cancers. A greater understanding of the molecular mechanisms underlying cancer cell spreading is needed as 90% of cancer‐associated deaths result from metastasis. We previously demonstrated that the Tamoxifen‐selected, MCF‐7 derivative, TMX2‐28, lacks expression of estrogen receptor α (ERα) and is highly invasive, yet maintains an epithelial morphology. ...
Source: Journal of Cellular Biochemistry - April 16, 2013 Category: Biochemistry Authors: Katerina D. Fagan‐Solis, Sallie Smith Schneider, Brian T. Pentecost, Brook A. Bentley, Christopher N. Otis, John F. Gierthy, Kathleen F. Arcaro Tags: Article Source Type: research
RON confers lapatinib resistance in HER2-positive breast cancer cells
Highlights: Abstract: Lapatinib-resistance is a major problem for HER2-positive breast cancer treatment. SK-BR-3-LR, a lapatinib-resistant cell clone, was established from HER2-positive SK-BR-3 breast cancer cells following chronic exposure to lapatinib. The PI3K/AKT signaling pathway was demonstrated to be resistant to HER2 inhibition in SK-BR-3-LR cells. However, both small-molecular Recepteur d’Origine Nantais (RON) inhibitors and RON-targeted small interfering RNA (siRNA) effectively restored lapatinib sensitivity in these cells by inhibiting PI3K/AKT activation. Our results demonstrate for the first time the importa...
Source: Cancer Letters - July 15, 2013 Category: Cancer & Oncology Authors: Quanren Wang, Haitian Quan, Jie Zhao, Chengying Xie, Lei Wang, Liguang Lou Tags: Research Articles Source Type: research
Heregulin Induces Resistance to Lapatinib‐mediated Growth Inhibition of HER2‐Amplified Cancer Cells
This article is protected by copyright. All rights reserved.
Source: Cancer Science - September 24, 2013 Category: Cancer & Oncology Authors: Yuji Sato, Masakazu Yashiro, Nobuyuki Takakura Tags: Original Article Source Type: research
The MAPK Pathway Is a Predominant Regulator of HLA-A Expression in Esophageal and Gastric Cancer.
In conclusion, HLA-A expression is predominantly regulated by the MAPK pathway in gastric and esophageal cancer.
PMID: 24244023 [PubMed - as supplied by publisher]
Source: Journal of Immunology - November 15, 2013 Category: Allergy & Immunology Authors: Mimura K, Shiraishi K, Mueller A, Izawa S, Kua LF, So J, Yong WP, Fujii H, Seliger B, Kiessling R, Kono K Tags: J Immunol Source Type: research
A display of pH-sensitive fusogenic GALA peptide facilitates endosomal escape from a Bio-nanocapsule via an endocytic uptake pathway
Conclusion:
The genetic fusion of a GALA peptide to the virus-like particle confers the ability of endosomal escape.
Source: Journal of Nanobiotechnology - April 1, 2014 Category: Nanotechnology Authors: Yuya NishimuraKoichi TakedaRyosuke EzawaJun IshiiChiaki OginoAkihiko Kondo Source Type: research
Breast cancer metastasis: demonstration that FOXP3 regulates CXCR4 expression and the response to CXCL12
This study was designed to examine the role FOXP3 plays in metastatic breast cancer, with a particular focus on its potential to regulate CXCR4. Human breast cancer samples showed significantly decreased FOXP3 protein expression but an increased number of CXCR4 transcripts. In comparison with normal primary breast epithelial cells, FOXP3 was down‐regulated at both transcript and protein levels in the breast cancer cell lines, MCF‐7 and MDA‐MB‐231. In the invasive MDA‐MB‐231 cells, the remaining FOXP3 was located predominately within the cytoplasm. Following stable FOXP3 over‐expression in MDA‐MB‐231 cells...
Source: The Journal of Pathology - May 28, 2014 Category: Pathology Authors: Stephen Douglass, Annette P Meeson, Dorota Overbeck‐Zubrzycka, John G Brain, Miriam R Bennett, Christopher A Lamb, Thomas WJ Lennard, David Browell, Simi Ali, John A Kirby Tags: Original Article Source Type: research
ARTN Mediates Acquired Resistance to Trastuzumab Cell Biology
Previous studies have demonstrated that Artemin (ARTN) functions as a cancer stem cell (CSC) and metastatic factor in mammary carcinoma. Herein, we report that ARTN mediates acquired resistance to trastuzumab in HER2-positive mammary carcinoma cells. Ligands that increase HER2 activity increased ARTN expression in HER2-positive mammary carcinoma cells, whereas trastuzumab inhibited ARTN expression. Forced expression of ARTN decreased the sensitivity of HER2-positive mammary carcinoma cells to trastuzumab both in vitro and in vivo. Conversely, siRNA-mediated depletion of ARTN enhanced trastuzumab efficacy. Cells with acquir...
Source: Journal of Biological Chemistry - June 5, 2014 Category: Chemistry Authors: Ding, K., Banerjee, A., Tan, S., Zhao, J., Zhuang, Q., Li, R., Qian, P., Liu, S., Wu, Z.-S., Lobie, P. E., Zhu, T. Tags: Molecular Bases of Disease Source Type: research
FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation
Conclusions:
As a novel Hsp90 inhibitor, FW-04-806 binds to the N-terminal of Hsp90 and inhibits Hsp90/Cdc37 interaction, resulting in the disassociation of Hsp90/Cdc37/client complexes and the degradation of Hsp90 client proteins. FW-04-806 displays promising antitumor activity against breast cancer cells both in vitro and in vivo, especially for HER2-overexpressed breast cancer cells.
Source: Molecular Cancer - June 14, 2014 Category: Cancer & Oncology Authors: Wei HuangMin YeLian-ru ZhangQun-dan WuMin ZhangJian-hua XuWei Zheng Source Type: research
The Epidermal Growth Factor Receptor Critically Regulates Endometrial Function during Early Pregnancy
by Michael J. Large, Margeaux Wetendorf, Rainer B. Lanz, Sean M. Hartig, Chad J. Creighton, Michael A. Mancini, Ertug Kovanci, Kuo-Fen Lee, David W. Threadgill, John P. Lydon, Jae-Wook Jeong, Francesco J. DeMayo
Infertility and adverse gynecological outcomes such as preeclampsia and miscarriage represent significant female reproductive health concerns. The spatiotemporal expression of growth factors indicates that they play an important role in pregnancy. The goal of this study is to define the role of the ERBB family of growth factor receptors in endometrial function. Using conditional ablation in mice and siRNA in prima...
Source: PLoS Genetics - June 19, 2014 Category: Genetics & Stem Cells Authors: Michael J. Large et al. Source Type: research
